

This press release constitutes a promotional communication and does not constitute a prospectus. This document must not be published, transmitted or distributed, directly or indirectly, in the United States, Canada, Australia or Japan.



Press release

Valbiotis announces the success of its capital increase of €10.2M, fully dedicated to supporting the commercial expansion of its range of scientifically tested natural healthcare products to prevent cardiometabolic imbalances

- Total demand of nearly €6.2M under the maintenance of preferential subscription rights
- Buoyed by the confidence of its shareholders, its institutional investors and its Chinese partner Xianhua Tao (through Ximen RD PTE Ltd, a company wholly owned by Xianhua Tao and a 51% shareholder alongside Valbiotis in the China-based joint venture), Valbiotis now has the resources to deliver on its strong short-term ambitions in France and internationally

La Rochelle, June 26, 2026 (6:00 PM CET) – Valbiotis (FR0013254851 – ALVAL, PEA/PME eligible), a French laboratory specializing in the design and distribution of scientifically tested natural healthcare products to prevent cardiometabolic imbalances and address everyday health issues, announces the success of its capital increase with shareholders' pre-emptive subscription rights maintained. This fundraising of €10.2M is intended to finance the acceleration of the Company's commercial development in France and internationally and support self-financed growth.

Sébastien Peltier, Chairman of the Board of Directors and Co-Founder of Valbiotis, comments:

"This successful fundraising further strengthens Valbiotis' rapid growth trajectory as we expand our commercial network and secure supply for our markets in France, Asia and the Middle East. I sincerely thank all the investors whose strong mobilization made this transaction possible: the institutional investors who secured it upstream; Xianhua Tao, whose personal participation further strengthens the strategic ties between Aika and Valbiotis; and our individual shareholders, whose loyalty and trust we are committed to honoring. We approach this acceleration phase with confidence and the conviction that Valbiotis has all the strengths needed to become a reference player in scientifically tested natural healthcare products."

OFFERING RESULTS

At the end of the subscription period, total demand on an irreducible, reducible and unrestricted basis amounted to 7,204,512 new shares subscribed at a unit price of €0.86, representing 60.85% of the maximum number of new shares to be subscribed, which was 11,840,000.

Total demand breaks down as follows:

- 4,265,714 shares requested on an irreducible basis, representing 36.0% of the total amount of the issue.
- 2,811,735 shares requested on a reducible basis, representing 23.7% of the total amount of the issue.
- 127,063 shares requested on an unrestricted basis, representing 1.1% of the total amount of the issue.

These subscription requests on an irreducible, reducible and unrestricted basis were satisfied in full.

It should be noted that the Company had received a subscription commitment for a total amount of €2.0M from Ximen RD PTE Ltd, a company wholly owned by Xianhua Tao and a 51% shareholder alongside Valbiotis in the China-based joint venture.

As subscription requests on an irreducible, reducible and unrestricted basis represented approximately 60.8% of the amount of the issue, that is, €6.2M, a total of 4,635,488 new shares, representing 39.2% of

This press release and the information it contains do not constitute a solicitation of an order to purchase or subscribe for securities in France or in any country other than France.

This press release constitutes a promotional communication and does not constitute a prospectus. This document must not be published, transmitted or distributed, directly or indirectly, in the United States, Canada, Australia or Japan.

the amount of the issue, were allocated and attributed to the shareholders and investors who had committed to subscribe under the issue guarantee, together the “Guarantors”. These guarantee commitments could be called upon if the number of new shares subscribed at the end of a subscription period does not reach 100% of the maximum amount of the capital increase.

As indicated in the press release announcing the launch of the capital increase, the 4,635,488 new shares allocated to the Guarantors, representing approximately €4.0M and corresponding to an allocation rate of 74.6% of the commitments received from the Guarantors, were distributed among them on a pro rata basis.

Out of the €5,797K in guarantee commitments received by the Company, the final allocations to the Guarantors are as follows, it being specified that the commitment made by Avenir France PME, managed by Talence Patival, to subscribe under the guarantee for €450K is included in the amount of subscriptions on a reducible basis:

Name	Allocations under the guarantee	Subscriptions on a reducible basis
Vatel Capital	€2,237K	
TreeCap B.V.	€559K	
Avenir France PME, managed by Talence Patival	-	€450K
Market Wizards B.V.	€224K	
Finaltis	€197K	
Gestys	€186K	
Maitice Gestion	€186K	
Nice & Green	€186K	
MW Gestion	€107K	
Sully Patrimoine Gestion	€67K	
Giga Società Semplice	€37K	
TOTAL	€3,987K	€450K

As a result, the total number of shares allocated under the capital increase is 11,840,000 and the allocation summary is as follows:

	Number of securities allocated	Corresponding amounts
Subscriptions on an irreducible, reducible (1) and unrestricted basis	7,204,512	€6,196K
Subscriptions under the guarantee	4,635,488	€3,987K
	11,840,000	€10,182K

(1) Including €450K in respect of the subscription guarantee commitment given by Avenir France, managed by Talence Patival

REMINDER OF THE USE OF THE OFFERING PROCEEDS

The net proceeds of the issue will amount to approximately €8.9 M and will support the Company’s commercial expansion. The funds raised will be allocated to the following objectives:

- 62% will be allocated to financing customer and inventory working capital requirements, in particular securing the plant supply chain; this expected increase in working capital requirements reflects the need to maintain inventory levels in line with our commercial ambitions in France and internationally.

This press release and the information it contains do not constitute a solicitation of an order to purchase or subscribe for securities in France or in any country other than France.

This press release constitutes a promotional communication and does not constitute a prospectus. This document must not be published, transmitted or distributed, directly or indirectly, in the United States, Canada, Australia or Japan.

- 25% will be allocated to strengthening the target sales force network, from 16 to 25 medical promotion officers, to achieve our revenue growth objectives and expand the Brand's presence in France.
- 13% will be allocated to marketing and communications expenses to support the rollout of the offering.

Given the cash position available at the end of April 2026, the expected acceleration of business in line with the strategic plan already communicated and the financial debt repayment schedule, the Company believes that the net proceeds of the Offering, namely €8.9 M, will provide a cash runway extending beyond the third quarter of 2027, not including any potential non-dilutive financing sources that remain to be determined and negotiated, with the Company maintaining its objective of positive EBITDA for fiscal year 2027

SETTLEMENT-DELIVERY

Settlement-delivery and admission of the new shares to trading on the Euronext Growth Paris market are scheduled for June 30, 2026. The new shares will carry current dividend rights, will be immediately assimilated with the Company's existing shares and will be traded on the same listing line as those shares under the same ISIN code (FR0013254851 – Ticker: ALVAL).

Following settlement-delivery, the Company's share capital will amount to €3,553,823.40 and will be divided into 35,538,234 ordinary shares with a par value of €0.10 each.

IMPACT OF THE TRANSACTION ON THE SHAREHOLDING STRUCTURE

To the Company's knowledge, the breakdown of share capital and voting rights before and after completion of the capital increase is as follows.

Impact of the Offering on the breakdown of share capital

Shareholders	Before the Offering		After the Offering	
	Number of shares	% of share capital	Number of shares	% of share capital
Members of the Board of Directors (1)	799,003	3.37%	799,003	2.25%
Including Djanka Investissement (controlled by Sébastien Peltier)	683,317	2.88%	683,317	1.92%
Including Sébastien Peltier	39,248	0.17%	39,248	0.11%
Ximen RD PTE Ltd (2)			2,325,581	6.54%
Employees (3)	89,822	0.38%	89,822	0.25%
Public	22,770,608	96.09%	32,285,027	90.85%
Liquidity agreement (May 31, 2026)	38,801	0.16%	38,801	0.11%
TOTAL	23,698,234	100.00%	35,538,234	100.00%

(1) *Members of the Board of Directors not acting in concert.*

(2) *Company wholly owned by Xianhua Tao, a 51% shareholder alongside Valbiotis in the China-based joint venture.*

(3) *Shares held in registered form only.*

This press release and the information it contains do not constitute a solicitation of an order to purchase or subscribe for securities in France or in any country other than France.

This press release constitutes a promotional communication and does not constitute a prospectus. This document must not be published, transmitted or distributed, directly or indirectly, in the United States, Canada, Australia or Japan.

Impact of the Offering on the breakdown of voting rights

Shareholders	Before the Offering		After the Offering	
	Number of voting rights	% of voting rights	Number of voting rights	% of voting rights
Members of the Board of Directors (1)	1,419,953	5.83%	1,419,953	3.92%
Including Djanka Investissement (controlled by Sébastien Peltier)	1,288,317	5.29%	1,288,317	3.56%
Including Sébastien Peltier	39,248	0.16%	39,248	0.11%
Ximen RD PTE Ltd (2)			2,325,581	6.42%
Employees (3)	94,386	0.39%	94,386	0.26%
Public	22,857,559	93.79%	32,371,978	89.40%
Liquidity agreement (as of May 31, 2026)	-	0.00%		
TOTAL	24,371,898	100.00%	36,211,898	100.00%

(1) Members of the Board of Directors not acting in concert.

(2) Company wholly owned by Xianhua Tao, a 51% shareholder alongside Valbiotis in the China-based joint venture.

(3) Shares held in registered form only.

IMPACT OF THE OFFERING ON CONSOLIDATED EQUITY PER SHARE

Dilutive impacts of the Offering	Consolidated equity per share as of December 31, 2025	
	Non-diluted basis	Diluted basis ⁽¹⁾
Before the Offering	€0.29	€0.45
After the Offering ⁽²⁾	€0.48	€0.58

(1) Taking into account the full exercise of all outstanding securities giving access to the share capital as of today, including free shares and BSPCEs, which could result in the issuance of a total of 1,439,856 shares.

(2) Before deduction of issuance premium expenses

IMPACT OF THE OFFERING ON THE POSITION OF A SHAREHOLDER HOLDING 1% OF THE SHARE CAPITAL AND NOT SUBSCRIBING TO THE OFFERING

Dilutive impacts of the Offering	Shareholder's interest	
	Non-diluted basis	Diluted basis ⁽¹⁾
Before the Offering	1.00%	0.94%
After the Offering	0.67%	0.64%

(1) Taking into account the full exercise of all outstanding securities giving access to the share capital as of today, including free shares and BSPCEs, which could result in the issuance of a total of 1,439,856 shares.

LOCK-UP AND HOLDING COMMITMENTS

Sébastien Peltier, Chairman of the Board of Directors, has undertaken to retain the shares he will hold through his holding company Djanka Investissement following this issuance for a period of 180 days after the settlement-delivery date of the capital increase.

In addition, the Company has undertaken a 180-day standstill commitment following the settlement-delivery date of the capital increase, subject to customary exceptions.

This press release and the information it contains do not constitute a solicitation of an order to purchase or subscribe for securities in France or in any country other than France.

This press release constitutes a promotional communication and does not constitute a prospectus. This document must not be published, transmitted or distributed, directly or indirectly, in the United States, Canada, Australia or Japan.

PROSPECTUS

The transaction does not require a prospectus subject to AMF approval, as the total amount of the offering calculated over a twelve-month period does not exceed €12M.

RISK FACTORS

The Company notes that the risk factors relating to the Company and its business are detailed in the Universal Registration Document for fiscal year 2025 (Chapter 3), available on the Company's website (www.valbiotis.com) under the Investors / Regulated Information section ([Registration Document](#)). The occurrence of all or part of these risks could have an adverse effect on the Company's business, financial position, results, development or outlook. The risk factors presented in the above-mentioned document remain unchanged as of the date of this press release.

SHARE INFORMATION

- Name: VALBIOTIS
- ISIN code and ticker symbol: FR0013254851 - ALVAL
- Listing venue: Euronext Growth Paris
- LEI code: 969500VP4JBJCF0MOP60

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. These statements do not constitute historical facts. These statements include projections and estimates, as well as the assumptions on which they are based, including statements relating, in particular, to plans, objectives, intentions and expectations regarding financial results, product potential or future performance. These forward-looking statements can often be identified by the words “expect”, “anticipate”, “believe”, “intend”, “estimate” or “plan”, as well as by other similar terms. Although VALBIOTIS' management believes that these forward-looking statements are reasonable, investors are advised that they are subject to numerous risks and uncertainties, which are difficult to predict and generally beyond VALBIOTIS' control, and which could cause actual results and events to differ materially from those expressed, implied or forecast in the forward-looking information and statements. These risks and uncertainties include, in particular, those developed or identified in the Universal Registration Document for fiscal year 2025 (Chapter 3), available on the Company's website (www.valbiotis.com) under the Investors / Regulated Information section. Valbiotis undertakes no obligation to update any forward-looking information or statements, subject to applicable regulations, in particular Articles 223-1 et seq. of the General Regulation of the French Financial Markets Authority.

WARNING

This press release does not constitute an offer to sell or a solicitation of an offer to buy, and no sale of common shares will take place in any state or jurisdiction in which such offer, solicitation or sale would be unlawful without registration or approval under the securities laws of such state or jurisdiction.

The distribution of this press release may be subject to specific regulations in certain countries. Persons in possession of this document are required to inform themselves of any such local restrictions and to comply with them.

This press release and the information it contains do not constitute a solicitation of an order to purchase or subscribe for securities in France or in any country other than France.

This press release constitutes a promotional communication and does not constitute a prospectus. This document must not be published, transmitted or distributed, directly or indirectly, in the United States, Canada, Australia or Japan.

This press release constitutes a promotional communication and not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017, as amended (the Prospectus Regulation).

With respect to Member States of the European Economic Area other than France (the Member States), no action has been taken or will be taken to permit a public offering of the securities requiring the publication of a prospectus in any such Member State. Accordingly, the securities may not be offered and will not be offered in any Member State (other than France), except in accordance with the exemptions provided for in Article 1(4) of the Prospectus Regulation, or in other cases not requiring the publication by Valbiotis of a prospectus under the Prospectus Regulation and/or the regulations applicable in such Member States. This press release does not constitute a public offering of securities in the United Kingdom.

This press release may not be published, distributed or released in the United States (including its territories and possessions). This press release does not constitute an offer or a solicitation to buy, sell or subscribe securities in the United States. The financial securities referred to in this press release have not been registered under the U.S. Securities Act of 1933, as amended (the Securities Act), or under any applicable securities regulations of any state or other jurisdiction in the United States and may not be offered or sold in the United States absent registration under the Securities Act except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Valbiotis does not intend to register the offering in whole or in part in the United States under and in accordance with the Securities Act, or to conduct a public offering in the United States.

This press release may not be distributed, directly or indirectly, in the United States, Canada, Australia or Japan.

Lastly, this press release may be prepared in both French and English. In the event of any differences between the two texts, the French version shall prevail.

TRANSACTION PARTNERS



PORTZAMPARC
BNP PARIBAS GROUP

Global Coordinator, Lead manager and
Joint Bookrunner



INVEST
SECURITIES

Global Coordinator, Lead manager
and Joint Bookrunner

ALLEGRA
F i n a n c e

Listing Sponsor

SEITOSEI . ACTIFIN

Financial Communications Agency

About Valbiotis

Valbiotis is a French laboratory specializing in the development and distribution of scientifically tested first-line nutritional solutions designed to prevent cardiometabolic imbalances. Through an innovative approach combining scientific excellence, plant expertise and a wealth of natural ingredients, Valbiotis develops high-quality formulations based on patented active ingredients validated by rigorous clinical studies, designed to provide long-term support for cardiometabolic health and address associated functional issues such as sleep, fatigue, mood management, immunity and vitality. Created at the beginning of 2014 in La Rochelle, France, Valbiotis has forged numerous partnerships with leading academic centers.

Valbiotis is a member of the “BPI Excellence” network and has been recognized as an “Innovative Company” by the BPI label. Valbiotis has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-PME eligible company.

For more information on Valbiotis®, please visit: www.valbiotis.com

This press release and the information it contains do not constitute a solicitation of an order to purchase or subscribe for securities in France or in any country other than France.

This press release constitutes a promotional communication and does not constitute a prospectus. This document must not be published, transmitted or distributed, directly or indirectly, in the United States, Canada, Australia or Japan.

Contacts

Corporate Communications / Valbiotis

Caroline Lamberti

+33 6 77 82 56 88

caroline.lamberti@valbiotis.com

Financial Communications / Seitosei-Actifin

Marianne Py

+33 6 85 52 76 93

marianne.py@seitosei-actifin.com

Press Relations / Seitosei-Actifin

Enora Budet

+33 6 72 17 84 60

enora.budet@seitosei-actifin.com